Relatlimab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Melanoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Non-Small Cell Lung Cancer · Phase 3

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (4)
Melanoma
NCT05625399 · Bristol-Myers Squibb
2023-03-06 – 2027-11-18 · Melanoma
What this study did
NCT05002569 · Bristol-Myers Squibb
2021-10-19 – 2025-04-02 · Melanoma
What this study did
Non-Small Cell Lung Cancer
Other / comorbidity
NCT05328908 · Bristol-Myers Squibb
2022-04-28 – 2025-07-14 · Colorectal Neoplasms
What this study did
Phase 2/3 (2)
Melanoma
Other / comorbidity
NCT05987241 · National Cancer Institute (NCI)
2024-02-02 – 2030-09-02 · Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
What this study did
Phase 2 (50)
Melanoma
NCT06999980 · Melanoma Institute Australia
2026-02-09 – 2038-01 · Cutaneous Melanoma, Mucosal Melanoma
What this study did
NCT05418972 · Melanoma Institute Australia
2023-08-14 – 2035-10 · Stage II Melanoma
What this study did
NCT07504796 · NYU Langone Health
2026-04-13 – 2031-05 · Metastatic Melanoma, Advanced Melanoma
What this study did
NCT06712927 · Stanford University
2025-08-06 – 2030-02 · Melanoma, Brain Metastases
What this study did
NCT05034536 · Massachusetts General Hospital
2022-02-07 – 2028-12-31 · Metastatic Melanoma
What this study did
NCT06295159 · H. Lee Moffitt Cancer Center and Research Institute
2024-05-17 – 2028-11 · Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma, Melanoma
What this study did
NCT05704647 · M.D. Anderson Cancer Center
2023-02-23 – 2028-07-31 · Melanoma (Skin)
What this study did
NCT05428007 · NYU Langone Health
2023-02-02 – 2028-03-17 · Melanoma, Unresectable Melanoma
What this study did
NCT02465060 · National Cancer Institute (NCI)
2015-08-17 – 2027-12-31 · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
What this study did
NCT05912244 · Memorial Sloan Kettering Cancer Center
2023-06-09 – 2027-06-09 · Melanoma
What this study did
NCT06101134 · Bristol-Myers Squibb
2023-11-06 – 2026-12-21 · Melanoma
What this study did
NCT04552223 · Jose Lutzky, MD
2020-11-10 – 2026-01-04 · Metastatic Uveal Melanoma
What this study did
NCT02519322 · M.D. Anderson Cancer Center
2016-02-02 – 2023-01-26 · Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma, Stage III Acral Lentiginous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Uveal Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IIIC Uveal Melanoma AJCC v7, Stage IV Acral Lentiginous Melanoma AJCC v6 and v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Uveal Melanoma AJCC v7
What this study did
NCT03724968 · Elizabeth Davis
2019-01-17 – 2020-05-28 · Metastatic Melanoma, Advanced Melanoma, Metastatic Melanoma Stratified by MHC-II Expression
What this study did
Non-Small Cell Lung Cancer
NCT03645928 · Iovance Biotherapeutics, Inc.
2019-05-07 – 2026-02-20 · Metastatic Melanoma, Squamous Cell Carcinoma of the Head and Neck, Non-small Cell Lung Cancer
What this study did
NCT04205552 · University Hospital, Essen
2020-03-04 – 2025-11-27 · NSCLC Stage II, NSCLC, Stage IIIA, NSCLC, Stage I
What this study did
NCT02750514 · Bristol-Myers Squibb
2016-05-09 – 2020-01-29 · Advanced Cancer
What this study did
Other / comorbidity
NCT07369791 · National Health Research Institutes, Taiwan
2026-12 – 2040-12 · Advanced Biliary Tract Cancer(BTC)
What this study did
NCT07644312 · Nationwide Children's Hospital
2027-03-01 – 2038-03-01 · High Grade Glioma, Diffuse Intrinsic Pontine Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma, Replication Repair Deficient
What this study did
NCT06288191 · Melanoma Institute Australia
2024-06-21 – 2036-07 · Cutaneous Squamous Cell Carcinoma
What this study did
NCT06151236 · Melanoma Institute Australia
2024-03-11 – 2034-04 · Merkel Cell Carcinoma
What this study did
NCT03521830 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2018-11-27 – 2032-07 · Basal Cell Carcinoma
What this study did
NCT03026140 · The Netherlands Cancer Institute
2017-03-29 – 2032-03-01 · Colon Carcinoma
What this study did
NCT06816927 · Duke University
2025-11-28 – 2031-06-01 · Newly Diagnosed Glioblastoma
What this study did
NCT06715241 · ARCAGY/ GINECO GROUP
2024-12-11 – 2030-12-31 · LOCALLY ADVANCED CERVICAL CANCERS
What this study did
NCT03899155 · Bristol-Myers Squibb
2019-08-09 – 2029-08-25 · Cancer
What this study did
NCT06325683 · National Cancer Institute (NCI)
2024-11-08 – 2029-07-15 · Progressive Glioblastoma, Recurrent Glioblastoma
What this study did
NCT06029270 · National Cancer Institute (NCI)
2024-07-15 – 2029-04-30 · Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8
What this study did
NCT05148546 · The Netherlands Cancer Institute
2022-04-28 – 2029-04 · Renal Cell Carcinoma
What this study did
NCT06708949 · M.D. Anderson Cancer Center
2025-03-20 – 2028-12-15 · Renal Cell Carcinoma, Clear Cell
What this study did
NCT06237920 · The Netherlands Cancer Institute
2024-02-19 – 2028-08-01 · Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Urogenital Diseases, Urinary Bladder Diseases, Male Urogenital Diseases, Urinary Bladder Neoplasm, Antineoplastics Toxicity
What this study did
NCT06624475 · University of California, San Diego
2025-08-21 – 2028-05 · Basal Cell Carcinoma
What this study did
NCT04080804 · Dan Zandberg
2019-12-20 – 2028-04-13 · Head and Neck Squamous Cell Carcinoma (HNSCC)
What this study did
NCT04204837 · Salzburger Landeskliniken
2017-03-06 – 2027-12 · Squamous Cell Carcinoma of the Skin
What this study did
NCT03607890 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2018-11-16 – 2027-10 · Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors
What this study did
NCT05347212 · M.D. Anderson Cancer Center
2022-09-22 – 2027-07-16 · Carcinomas, Renal Medullary Carcinoma
What this study did
NCT04953104 · M.D. Anderson Cancer Center
2021-09-21 – 2026-12-31 · Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma, Unresectable Urothelial Carcinoma
What this study did
NCT04095208 · Institut Bergonié
2020-02-27 – 2026-03-29 · Soft Tissue Sarcoma Adult, Advanced Cancer
What this study did
NCT04913922 · Ludwig-Maximilians - University of Munich
2021-05-05 – 2026-03 · Acute Myeloid Leukemia
What this study did
NCT04567615 · Bristol-Myers Squibb
2021-02-04 – 2025-11-19 · Hepatocellular Carcinoma, Hepatoma, Liver Cancer, Adult, Liver Cell Carcinoma, Liver Cell Carcinoma, Adult
What this study did
NCT04062656 · University Hospital, Essen
2019-09-26 – 2025-06-01 · Gastric Cancer, Adenocarcinoma of the Esophagogastric Junction
What this study did
NCT03704077 · Bristol-Myers Squibb
2019-10-31 – 2024-09-30 · Gastric Cancer, Cancer of the Stomach, Stomach Cancer, Gastroesophageal Junction
What this study did
NCT03642067 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2019-02-12 – 2024-09-18 · Microsatellite Stable (MSS) Colorectal Adenocarcinomas, Colorectal Adenocarcinoma
What this study did
NCT04326257 · Dan Zandberg
2020-05-14 – 2024-08-12 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT03623854 · Jonsson Comprehensive Cancer Center
2019-04-03 – 2023-09-28 · Chordoma, Locally Advanced Chordoma, Metastatic Chordoma, Unresectable Chordoma
What this study did
NCT06400264 · National Cancer Institute (NCI)
2022-02-22 – 2023-01-17 · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
What this study did
NCT02935634 · Bristol-Myers Squibb
2016-11-29 – 2022-05-11 · Advanced Gastric Cancer
What this study did
NCT02996110 · Bristol-Myers Squibb
2017-02-02 – 2021-11-23 · Advanced Cancer
What this study did
Phase 1/2 (13)
Melanoma
NCT06683755 · M.D. Anderson Cancer Center
2024-12-31 – 2032-08-16 · Melanoma
What this study did
NCT07281924 · University of Wisconsin, Madison
2026-11 – 2030-12 · Metastatic Melanoma, Liver Metastases
What this study did
Other / comorbidity
NCT06963905 · Yale University
2025-12-29 – 2030-12 · Metastatic Triple-negative Breast Cancer
What this study did
NCT03610711 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2019-03-06 – 2027-12 · Gastroesophageal Cancer, Immune Checkpoint Inhibition
What this study did
NCT05255601 · Bristol-Myers Squibb
2022-09-13 – 2025-12-03 · Lymphoma, Non-Hodgkin, Hodgkin Disease
What this study did
NCT05337137 · Bristol-Myers Squibb
2022-05-05 – 2025-11-18 · Carcinoma, Hepatocellular
What this study did
NCT03459222 · Bristol-Myers Squibb
2018-05-30 – 2025-02-19 · Advanced Cancer
What this study did
NCT04150965 · Multiple Myeloma Research Consortium
2020-07-10 – 2024-08-30 · Multiple Myeloma, Relapsed Refractory Multiple Myeloma
What this study did
NCT04611126 · Inge Marie Svane
2021-04-22 – 2024-03-03 · Metastatic Ovarian Cancer, Metastatic Fallopian Tube Cancer, Peritoneal Cancer
What this study did
NCT03310619 · Celgene
2017-12-20 – 2023-02-15 · Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
What this study did
NCT02488759 · Bristol-Myers Squibb
2015-10-13 – 2022-10-24 · Various Advanced Cancer
What this study did
NCT02061761 · Bristol-Myers Squibb
2014-03-13 – 2022-02-16 · Hematologic Neoplasms
What this study did
Phase 1 (12)
Melanoma
NCT04697576 · Carlo Contreras
2021-10-20 – 2027-12-31 · Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma
What this study did
NCT05704933 · H. Lee Moffitt Cancer Center and Research Institute
2023-06-06 – 2024-08-20 · Metastatic Melanoma, Metastasis to Brain
What this study did
NCT04935229 · TriSalus Life Sciences, Inc.
2021-08-02 – 2024-07-17 · Metastatic Uveal Melanoma in the Liver
What this study did
Non-Small Cell Lung Cancer
NCT05176483 · Exelixis
2021-12-14 – 2030-06-28 · Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
What this study did
Other / comorbidity
NCT04658147 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2021-05-28 – 2030-06-01 · Hepatocellular Carcinoma
What this study did
NCT03044613 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2017-07-11 – 2027-08 · Gastric Cancer, Esophageal Cancer, GastroEsophageal Cancer
What this study did
NCT02966548 · Bristol-Myers Squibb
2017-01-04 – 2024-07-09 · Cancer
What this study did
NCT05498480 · Bristol-Myers Squibb
2022-07-27 – 2024-01-18 · Advanced Solid Tumors
What this study did
NCT02658981 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2016-08-24 – 2023-10-03 · Glioblastoma, Gliosarcoma, Recurrent Brain Neoplasm
What this study did
NCT04112498 · Bristol-Myers Squibb
2019-10-01 – 2023-02-27 · Cancer
What this study did
NCT03335540 · Bristol-Myers Squibb
2018-05-07 – 2021-08-25 · Advanced Cancer
What this study did
Phase 4 (1)
Melanoma
NCT07459543 · Bristol-Myers Squibb
2026-11-15 – 2029-05-28 · Unresectable Melanoma, Metastatic Melanoma
What this study did
Used as active comparator (5)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (4)
Melanoma
NCT06246916 · Regeneron Pharmaceuticals
2024-09-09 – 2033-07-10 · Melanoma
What this study did
NCT06743126 · Immatics US, Inc.
2025-01-14 – 2032-08-12 · Melanoma, Cutaneous Malignant, Mucosal Melanoma
What this study did
NCT06264180 · Replimune, Inc.
2024-07-11 – 2031-03-31 · Advanced Melanoma
What this study did
NCT06112314 · Immunocore Ltd
2024-06-05 – 2027-10-16 · Advanced Melanoma
What this study did
Phase 2/3 (1)
Melanoma
NCT06624644 · Linnaeus Therapeutics, Inc.
2025-08-06 – 2031-02 · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma, Unresectable Melanoma
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Relatlimab: this drugPhase 3Monoclonal antibodyLAG-3Partial signal
NCT04623775: Part 2 objective response rate by BICR (RECIST 1.1): nivolumab + relatlimab + chemotherapy 50.6% (90% CI 43.8 to 57.4, n=158) vs nivolumab + chemotherapy 43.0% (90% CI 36.2 to 50.1, n=151); odds ratio 1.39 (90% CI 0.94 to 2.05). The Part 1 co-primary (TRAEs leading to discontinuation within 12 weeks) compares two relatlimab regimens: 5.6% vs 12.1% (CT.gov posted results). missed
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
Intismeran AutogenePhase 3VaccinePatient-specific tumor neoantigens (personalized, up to 34 per patient)not yet gradedNo reviewed efficacy summary in this indication
LNS8801
Phase 2/3(overall)
Small moleculeGPER (G protein-coupled estrogen receptor)not yet gradedNo reviewed efficacy summary in this indication
ResiquimodPhase 2/3Small moleculeToll-like receptor 7 and 8 (TLR7/8)not yet gradedNo reviewed efficacy summary in this indication
HLX26Phase 2Monoclonal antibodyLAG-3not yet gradedNo reviewed efficacy summary in this indication
Vusolimogene Oderparepvec (Tudriqev)Phase 2Oncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
EvalstotugPhase 1/2Biologic (subtype unspecified)CTLA-4not yet gradedNo reviewed efficacy summary in this indication
OBX-115Phase 1/2Cell therapyIL-15 receptor signalingnot yet gradedNo reviewed efficacy summary in this indication
VSV-IFNβ-NISPhase 1/2Oncolytic virusOncolytic VSV expressing interferon-beta and NISnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 1Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
GSK2831781
Discontinued
Monoclonal antibodyLAG-3
not yet graded(overall)
No reviewed efficacy summary in this indication
NaporafenibDiscontinuedSmall moleculePan-RAFWeak signal
NCT02607813: 142 patients were treated across the naporafenib dose-escalation (n = 87), naporafenib plus spartalizumab dose-escalation (n = 12) and dose-expansion (n = 43) arms. The maximum tolerated and recommended dose for single-agent naporafenib was 600 mg twice daily. Five patients in the naporafenib escalation arm had 7 dose-limiting toxicities, including decreased platelet count at 1200 mg once daily, neuralgia, maculopapular rash and pruritus at 600 mg twice daily, and increased blood bilirubin, hyponatremia and peripheral sensory neuropathy at 800 mg twice daily.

Large race: only the 72 furthest-along competitors are listed; 539 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(34 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Relatlimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (6)
November 2026 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2026-11 · NCT06712927 · CT.gov ↗
What to watch
December 2026 (5)
Phase 1/2Gastroesophageal Cancer, Immune Checkpoint InhibitionActive not recruiting
Est. primary completion 2026-12 · NCT03610711 · CT.gov ↗
What to watch
Phase 2Squamous Cell Carcinoma of the SkinRecruiting
Est. primary completion 2026-12 · NCT04204837 · CT.gov ↗
What to watch
Phase 2Merkel Cell CarcinomaRecruiting
Est. primary completion 2026-12 · NCT06151236 · CT.gov ↗
What to watch
Phase 2Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Neoplasms, Female Urogenital Diseases …Active not recruiting
Est. primary completion 2026-12-01 · NCT06237920 · CT.gov ↗
What to watch
Phase 2Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma …Active not recruiting
Est. primary completion 2026-12-31 · NCT04953104 · CT.gov ↗
What to watch
2027 (9)
January 2027 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01-31 · NCT05176483 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1Gastric Cancer, Esophageal Cancer, GastroEsophageal CancerActive not recruiting
Est. primary completion 2027-03 · NCT03044613 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-06-09 · NCT05912244 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-06-30 · NCT05034536 · CT.gov ↗
What to watch
July 2027 (2)
Phase 2Basal Cell CarcinomaRecruiting
Est. primary completion 2027-07 · NCT03521830 · CT.gov ↗
What to watch
Phase 2Carcinomas, Renal Medullary CarcinomaActive not recruiting
Est. primary completion 2027-07-16 · NCT05347212 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1MelanomaRecruiting
Est. primary completion 2027-09-30 · NCT04697576 · CT.gov ↗
What to watch
October 2027 (1)
Phase 2Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H TumorsActive not recruiting
Est. primary completion 2027-10 · NCT03607890 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-12-31 · NCT02465060 · CT.gov ↗
What to watch
2028 (6)
March 2028 (2)
Phase 2MelanomaRecruiting
Est. primary completion 2028-03 · NCT06999980 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2028-03-17 · NCT05428007 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Basal Cell CarcinomaRecruiting
Est. primary completion 2028-05 · NCT06624475 · CT.gov ↗
What to watch
July 2028 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2028-07-31 · NCT05704647 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2028-11 · NCT06295159 · CT.gov ↗
What to watch
December 2028 (1)
Phase 2Renal Cell Carcinoma, Clear CellActive not recruiting
Est. primary completion 2028-12-15 · NCT06708949 · CT.gov ↗
What to watch
2029 (5)
April 2029 (1)
Phase 2Metastatic Nasopharyngeal Carcinoma, Recurrent Nasopharyngeal Carcinoma, Stage IV Nasopharyngeal Carcinoma AJCC v8Recruiting
Est. primary completion 2029-04-30 · NCT06029270 · CT.gov ↗
What to watch
May 2029 (2)
Phase 2MelanomaRecruiting
Est. primary completion 2029-05 · NCT07504796 · CT.gov ↗
What to watch
Phase 4MelanomaNot yet recruiting
Est. primary completion 2029-05-26 · NCT07459543 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Newly Diagnosed GlioblastomaRecruiting
Est. primary completion 2029-06-01 · NCT06816927 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2CancerRecruiting
Est. primary completion 2029-08-25 · NCT03899155 · CT.gov ↗
What to watch
2030 (6)
July 2030 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-07-30 · NCT06561386 · CT.gov ↗
What to watch
August 2030 (1)
Phase 1/2MelanomaRecruiting
Est. primary completion 2030-08-16 · NCT06683755 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2/3Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma …Recruiting
Est. primary completion 2030-09-02 · NCT05987241 · CT.gov ↗
What to watch
December 2030 (3)
Phase 1/2Metastatic Triple-negative Breast CancerRecruiting
Est. primary completion 2030-12 · NCT06963905 · CT.gov ↗
What to watch
Phase 1/2MelanomaRecruiting
Est. primary completion 2030-12 · NCT07281924 · CT.gov ↗
What to watch
Phase 2LOCALLY ADVANCED CERVICAL CANCERSActive not recruiting
Est. primary completion 2030-12-31 · NCT06715241 · CT.gov ↗
What to watch
2032 (1)
March 2032 (1)
Phase 2Colon CarcinomaRecruiting
Est. primary completion 2032-03-01 · NCT03026140 · CT.gov ↗
What to watch
2033 (1)
March 2033 (1)
Phase 2High Grade Glioma, Diffuse Intrinsic Pontine Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma, Replication Repair DeficientNot yet recruiting
Est. primary completion 2033-03-01 · NCT07644312 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 February 2025Topline resultPhase 3 RELATIVITY-098 (NCT05002569) did not meet its primary endpoint of recurrence-free survival
Bristol Myers Squibb · Source ↗